A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS

Summary

This Phase 1 randomized, placebo-controlled, double-blind study will evaluate the PK/PD relationship of single doses of QRL-101 in 12 ALS participants. The study will also assess safety and tolerability in participants receiving either QRL-101 or placebo.

Timeline

Start

2024-11-11

Primary completion

2025-08-22

Completion

2025-08-22

Drugs

Indications